The unfolded protein response is activated in the olfactory system in Alzheimer’s disease

被引:0
作者
Helen C. Murray
Birger Victor Dieriks
Molly E. V. Swanson
Praju Vikas Anekal
Clinton Turner
Richard L. M. Faull
Leonardo Belluscio
Alan Koretsky
Maurice A. Curtis
机构
[1] University of Auckland,Department of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science
[2] National Institute of Neurological Disorders and Stroke,Laboratory of Functional and Molecular Imaging
[3] National Institutes of Health,Department of Anatomical Pathology, LabPlus
[4] Auckland City Hospital,undefined
[5] Howard Hughes Medical Institute,undefined
来源
Acta Neuropathologica Communications | / 8卷
关键词
Alzheimer’s disease; Unfolded protein response; Olfactory bulb; Anterior olfactory nucleus; PERK; eIF2α;
D O I
暂无
中图分类号
学科分类号
摘要
Olfactory dysfunction is an early and prevalent symptom of Alzheimer’s disease (AD) and the olfactory bulb is a nexus of beta-amyloid plaque and tau neurofibrillary tangle (NFT) pathology during early AD progression. To mitigate the accumulation of misfolded proteins, an endoplasmic reticulum stress response called the unfolded protein response (UPR) occurs in the AD hippocampus. However, chronic UPR activation can lead to apoptosis and the upregulation of beta-amyloid and tau production. Therefore, UPR activation in the olfactory system could be one of the first changes in AD. In this study, we investigated whether two proteins that signal UPR activation are expressed in the olfactory system of AD cases with low or high amounts of aggregate pathology. We used immunohistochemistry to label two markers of UPR activation (p-PERK and p-eIF2α) concomitantly with neuronal markers (NeuN and PGP9.5) and pathology markers (beta-amyloid and tau) in the olfactory bulb, piriform cortex, entorhinal cortex and the CA1 region of the hippocampus in AD and normal cases. We show that UPR activation, as indicated by p-PERK and p-eIF2α expression, is significantly increased throughout the olfactory system in AD cases with low (Braak stage III-IV) and high-level (Braak stage V-VI) pathology. We further show that UPR activation occurs in the mitral cells and in the anterior olfactory nucleus of the olfactory bulb where tau and amyloid pathology is abundant. However, UPR activation is not present in neurons when they contain NFTs and only rarely occurs in neurons containing diffuse tau aggregates. We conclude that UPR activation is prevalent in all regions of the olfactory system and support previous findings suggesting that UPR activation likely precedes NFT formation. Our data indicate that chronic UPR activation in the olfactory system might contribute to the olfactory dysfunction that occurs early in the pathogenesis of AD.
引用
收藏
相关论文
共 300 条
  • [1] Abisambra JF(2013)Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation J Neurosci 33 9498-9507
  • [2] Jinwal UK(2005)Olfactory involvement in aging and Alzheimer’s disease: an autopsy study J Alzheimers Dis 7 149-157
  • [3] Blair LJ(1987)Number of mitral cells and the bulb volume in the aging human olfactory bulb: a quantitative morphological study Anat Rec 218 73-87
  • [4] O’Leary JC(1995)Staging of Alzheimer’s disease-related neurofibrillary changes Neurobiol Aging 16 271-278
  • [5] Li Q(2002)Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages) J Neurol 249 Suppl III/1-5-211
  • [6] Brady S(2003)Staging of brain pathology related to sporadic Parkinson’s disease Neurobiol Aging 24 197-2254
  • [7] Wang L(2007)Abeta 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner Antioxid Redox Signal 9 2245-292
  • [8] Guidi CE(2018)The emerging roles of protein homeostasis-governing pathways in Alzheimer’s disease Aging Cell 17 277-1405
  • [9] Zhang B(2013)The unfolded protein response in Alzheimer’s disease Semin Immunopathol 35 1399-3481
  • [10] Nordhues BA(2000)Olfactory deficits in patients with mild cognitive impairment predict Alzheimer’s disease at follow-up Am J Psychiatry 157 3127-60